Oct 19 (Reuters) – Hong Kong-listed Metis TechBio on Monday said it has entered a collaboration agreement with Eli Lilly worth up to $1.1 billion for the research and development of tissue-specific drug delivery technologies.
(Reporting by Nikita Maria Jino in Bengaluru; Editing by Joyjeet Das)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.
